BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2075 related articles for article (PubMed ID: 25777974)

  • 1. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.
    Parker K; Gallop-Evans E; Hanna L; Adams M
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):140-6. PubMed ID: 18922646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors.
    Teh J; Yap SP; Tham I; Sethi VK; Chua EJ; Yeo R; Ho TH; Tay EH; Chia YN; Soh LT; Khoo-Tan HS
    Int J Gynecol Cancer; 2010 Apr; 20(3):428-33. PubMed ID: 20375809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
    Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
    Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T; Lingying W; Manni H; Jusheng A; Ning L
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of treatment results and prognostic factors in early-stage cervical carcinoma patients treated with postoperative radiotherapy or radiochemotherapy.
    Demirci S; Ozsaran Z; Ozsaran A; Yavas F; Demircioglu B; Hanhan M; Dikmen Y; Aras AB
    Eur J Gynaecol Oncol; 2012; 33(1):62-7. PubMed ID: 22439408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-field intensity-modulated radiation therapy combined with concurrent chemotherapy for cervical cancer with para-aortic lymph nodes metastasis.
    Liu X; Wang W; Meng Q; Zhang F; Hu K
    Jpn J Clin Oncol; 2019 Mar; 49(3):263-269. PubMed ID: 30668725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
    Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
    Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial.
    Wang X; Shen Y; Zhao Y; Li Z; Gou H; Cao D; Yang Y; Qiu M; Li Q; Liu J; Yi C; Liao Z; Luo D; Xu F; Bi F
    Eur J Surg Oncol; 2015 Aug; 41(8):1082-8. PubMed ID: 26033265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.
    Phung HT; Truong MC; Nguyen LT; Dang ATV; Vu TH; Nguyen HT
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):853-859. PubMed ID: 33773550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy (3DCRT) and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma.
    Dracham CB; Mahajan R; Rai B; Elangovan A; Bhattacharya T; Ghoshal S
    Jpn J Clin Oncol; 2019 Feb; 49(2):146-152. PubMed ID: 30452664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Squamous Cell Carcinoma Antigen (SCC-Ag) as a Predictive Factor for the Use of Consolidation Chemotherapy in Cervical Cancer Patients After Postoperative Extended-Field Concurrent Chemoradiotherapy.
    Zhang G; Miao L; Wu H; Zhang Y; Fu C
    Technol Cancer Res Treat; 2021; 20():15330338211044626. PubMed ID: 34605696
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
    Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
    Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
    Hu K; Wang W; Liu X; Meng Q; Zhang F
    Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 104.